Bioasis Technologies (BIOAF) Stock Price, News & Analysis

Company Overview

Bioasis Technologies, Inc. (OTCMKTS: BIOAF) is a biotechnology company dedicated to developing therapies and diagnostic agents that effectively cross the blood–brain barrier (BBB). Leveraging its proprietary xB3™ platform, Bioasis designs biologics and small molecules with enhanced central nervous system (CNS) delivery capabilities. The company’s core mission is to address neurological disorders that have historically been challenging to treat due to limited drug penetration into the brain.

At the center of Bioasis’s pipeline is its lead program for Parkinson’s disease, which employs the xB3 delivery technology to transport therapeutic antibodies directly to affected brain regions. In addition to Parkinson’s therapeutics, Bioasis is advancing diagnostic imaging agents intended to improve early detection of Alzheimer’s disease and other neurodegenerative conditions. The company’s platform has also shown promise in veterinary medicine, where it supports treatments for canine cognitive dysfunction.

Headquartered in Vancouver, Canada, Bioasis collaborates with pharmaceutical and biotechnology partners worldwide, offering out-licensing opportunities and joint development agreements. Its research and development efforts are carried out in collaboration with leading academic institutions and contract research organizations across North America and Europe. These strategic partnerships aim to expand the reach of the xB3 platform and accelerate clinical programs.

Founded in the early 2000s, Bioasis traces its origins to blood–brain barrier research conducted at the University of Toronto and Sunnybrook Research Institute. The company is led by President and CEO Jeff Graham, who brings extensive experience in biotech leadership, and advises a scientific board that includes experts in neurology, pharmacology, and translational research. Under this leadership, Bioasis continues to pursue innovative solutions for CNS disorders and to build a pipeline of differentiated drug candidates.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $16 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BIOAF Stock Analysis - Frequently Asked Questions

How were Bioasis Technologies' earnings last quarter?

Bioasis Technologies Inc. (OTCMKTS:BIOAF) issued its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.01) EPS for the quarter, hitting analysts' consensus estimates of ($0.01).

How do I buy shares of Bioasis Technologies?

Shares of BIOAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 10/27/2021
• Today: 7/17/2025
• Fiscal Year End: 2/28/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BIOAF
• CIK: N/A
• Web: www.bioasis.us
• Phone: (203) 533-7082
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 79,410,000
• Free Float: N/A
• Market Cap: $16 thousand
• Optionable: Not Optionable
• Beta: 0.50